Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

REDWOOD CITY, Calif. and TOKYO, May 7, 2012 /PRNewswire/ -- Coherus BioSciences, Inc (hereafter, Coherus BioSciences) and Daiichi Sankyo, Co. Ltd. (hereafter, Daiichi Sankyo; TSE 4568) announced today the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

Under the terms of the agreement, Daiichi Sankyo and Coherus BioSciences will work together to develop, manufacture and commercialize  biosimilar forms of etanercept and rituximab developed by Coherus BioSciences. Upon marketing approval, Daiichi Sankyo will commercialize these products in Japan, South Korea and Taiwan. Coherus has retained all additional development and commercial rights outside of the licensed territories.  Specific financial terms of the agreement were not disclosed.

"This collaboration to develop and commercialize these biosimilar candidates with a leading global healthcare company such as Daiichi Sankyo is a significant strategic event for Coherus BioSciences and validates our unique business model strategy," said Denny Lanfear, Chief Executive Officer.  "This agreement demonstrates that our strategy and model position us well to make a major impact toward providing access to biosimilar therapies for patients on a global basis."

"Coherus BioSciences has established an outstanding business model, a very experienced biologic development team and outstanding capabilities," said Joji Nakayama, President & CEO of Daiichi Sankyo. "By creating an opportunity for an early entry into the biosimilars market, this agreement will strengthen our internal platform for manufacturing and developing biopharmaceuticals, leading directly to the introduction of other biosimilars therapies in the future."

Sagent Advisors
'/>"/>

SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK , ... (NASDAQ:  PTBI), a biopharmaceutical company advancing protein biologic ... an overview of the Company,s 2014 achievements and ... below demonstrate the progress the Company has made ... corporate partnerships for its MuGard programs, the FDA ...
(Date:4/1/2015)... NEW YORK CITY and LONDON ... of market research reports and solutions, MarketResearch.com is pleased to ... will be a year of market growth and opportunity for ... stem cell company or cord blood bank, competing in the ... market conditions, predict industry trends, and act on market changes ...
(Date:4/1/2015)... OXFORD, England , April 1, 2015 /PRNewswire/ ... world-leading biotechnology company developing novel biological drugs to ... today pleased to announce the appointment of ... Coughlin will be responsible for providing medical and ... for the Company. Dr. Coughlin has ...
(Date:3/31/2015)... 2015 Eastern Kentucky University is ... bachelor’s of criminal justice degree programs by Nonprofitcollegesonline.com. ... inspiring ideas and high quality educational opportunities,” Editor ... University. We are confident that students will find ... is the site’s first “Students before Profits” list, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... the Company,s request for an,extension until December 3, ... market capitalization requirement of $35 million or the ... order to remain,listed. There can be no assurance ...
... Aortic ... Aneurysms, ... of Vascular Surgery was the first to implant, in,Phoenix, the Powerlink ... aortic aneurysms (AAA). The procedure was,performed at Arizona Heart Hospital by ...
... BOSTON, Oct. 31 PAREXEL International,Corporation (Nasdaq: ... at the,Oppenheimer 19th Annual Healthcare Conference in New ... Financial Officer will be making,a formal presentation on ... 3,2008., The presentation will be available under ...
Cached Biology Technology:Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... 2012 Childhood Obesity , a peer-reviewed journal from Mary ... dedicated to the role that schools can and should ... eating habits to help stem the tide of the ... provides comprehensive coverage of food policy, systems, and programs ...
... becomes extinct, other predatory species could soon follow, according to ... a University of Exeter team has now carried out the ... 2012) in the Royal Society journal Biology Letters , ... can indirectly cause another to become extinct. The University of ...
... Biofuels and Texas AgriLife Research, part of The Texas ... develop and commercialize cellulosic feedstocks for the production of ... diverse high biomass energy crop breeding program and BP ... companies growing commercial-scale biomass crops for liquid fuels. ...
Cached Biology News:School food -- on the front line in the fight against childhood obesity 2Study proves that 1 extinction leads to another 2BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: